KR102531354B1 - Er+ 유방암의 라소폭시펜 치료 - Google Patents

Er+ 유방암의 라소폭시펜 치료 Download PDF

Info

Publication number
KR102531354B1
KR102531354B1 KR1020237008605A KR20237008605A KR102531354B1 KR 102531354 B1 KR102531354 B1 KR 102531354B1 KR 1020237008605 A KR1020237008605 A KR 1020237008605A KR 20237008605 A KR20237008605 A KR 20237008605A KR 102531354 B1 KR102531354 B1 KR 102531354B1
Authority
KR
South Korea
Prior art keywords
patient
lasofoxifene
inhibitor
certain embodiments
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020237008605A
Other languages
English (en)
Korean (ko)
Other versions
KR20230042390A (ko
Inventor
케이틀린 안드레아노
칭-이 창
도날드 피. 맥도넬
스테파니 엘. 게일라드
Original Assignee
듀크 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 듀크 유니버시티 filed Critical 듀크 유니버시티
Publication of KR20230042390A publication Critical patent/KR20230042390A/ko
Application granted granted Critical
Publication of KR102531354B1 publication Critical patent/KR102531354B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/402—1-aryl substituted, e.g. piretanide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
KR1020237008605A 2016-10-11 2017-10-10 Er+ 유방암의 라소폭시펜 치료 Active KR102531354B1 (ko)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201662406859P 2016-10-11 2016-10-11
US62/406,859 2016-10-11
US201762457759P 2017-02-10 2017-02-10
US62/457,759 2017-02-10
US201762502299P 2017-05-05 2017-05-05
US62/502,299 2017-05-05
PCT/US2017/055970 WO2018093484A1 (en) 2016-10-11 2017-10-10 Lasofoxifene treatment of er+ breast cancer
KR1020227037620A KR102623130B1 (ko) 2016-10-11 2017-10-10 Er+ 유방암의 라소폭시펜 치료

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020227037620A Division KR102623130B1 (ko) 2016-10-11 2017-10-10 Er+ 유방암의 라소폭시펜 치료

Publications (2)

Publication Number Publication Date
KR20230042390A KR20230042390A (ko) 2023-03-28
KR102531354B1 true KR102531354B1 (ko) 2023-05-11

Family

ID=60186386

Family Applications (5)

Application Number Title Priority Date Filing Date
KR1020197013405A Active KR102285453B1 (ko) 2016-10-11 2017-10-10 Er+ 유방암의 라소폭시펜 치료
KR1020237008605A Active KR102531354B1 (ko) 2016-10-11 2017-10-10 Er+ 유방암의 라소폭시펜 치료
KR1020227037620A Active KR102623130B1 (ko) 2016-10-11 2017-10-10 Er+ 유방암의 라소폭시펜 치료
KR1020217023829A Active KR102462433B1 (ko) 2016-10-11 2017-10-10 Er+ 유방암의 라소폭시펜 치료
KR1020247000452A Pending KR20240007720A (ko) 2016-10-11 2017-10-10 Er+ 유방암의 라소폭시펜 치료

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020197013405A Active KR102285453B1 (ko) 2016-10-11 2017-10-10 Er+ 유방암의 라소폭시펜 치료

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020227037620A Active KR102623130B1 (ko) 2016-10-11 2017-10-10 Er+ 유방암의 라소폭시펜 치료
KR1020217023829A Active KR102462433B1 (ko) 2016-10-11 2017-10-10 Er+ 유방암의 라소폭시펜 치료
KR1020247000452A Pending KR20240007720A (ko) 2016-10-11 2017-10-10 Er+ 유방암의 라소폭시펜 치료

Country Status (20)

Country Link
US (8) US20190231718A1 (enExample)
EP (2) EP4035662A1 (enExample)
JP (4) JP6892151B2 (enExample)
KR (5) KR102285453B1 (enExample)
CN (3) CN112353796A (enExample)
AU (3) AU2017360365B2 (enExample)
BR (1) BR112019007254A2 (enExample)
CA (1) CA3040266A1 (enExample)
DK (1) DK3525774T3 (enExample)
ES (1) ES2909576T3 (enExample)
IL (2) IL284875B (enExample)
MX (2) MX387856B (enExample)
NZ (2) NZ793063A (enExample)
PL (1) PL3525774T3 (enExample)
PT (1) PT3525774T (enExample)
RU (1) RU2019114079A (enExample)
SG (2) SG10201913951YA (enExample)
TW (4) TWI896001B (enExample)
WO (2) WO2018093484A1 (enExample)
ZA (1) ZA201902454B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
IL284875B (en) 2016-10-11 2022-07-01 Univ Duke Zofoxifene treatment for breast cancer
EP3773524B1 (en) * 2018-04-10 2025-04-09 Duke University Lasofoxifene for the treatment of er+ breast cancer carrying the mutation d538g or y537s
CN114306245A (zh) 2020-09-29 2022-04-12 深圳市药欣生物科技有限公司 无定形固体分散体的药物组合物及其制备方法
GB202116903D0 (en) 2021-11-18 2022-01-05 Sermonix Pharmaceuticals Inc Lasofoxifene treatment of aromatase-resistant er+ cancer
EP4531848A1 (en) * 2022-05-25 2025-04-09 Sermonix Pharmaceuticals, Inc. Lasofoxifene combination treatment of er+ breast cancer that has progressed on a cdk4/6 inhibitor
WO2025075631A1 (en) 2023-10-06 2025-04-10 Sermonix Pharmaceuticals, Inc. Lasofoxifene treatment of endocrine therapy resistant er+ cancer
WO2025099483A1 (en) * 2023-11-06 2025-05-15 Centro De Investigación Y De Estudios Avanzados Del I.P.N. Use for raloxifene for the treatment of hepatic cancer
WO2025122504A1 (en) * 2023-12-04 2025-06-12 Foundation Medicine, Inc. Esr1 mutations, esr1 co-occurring mutations, and uses thereof
WO2025165887A1 (en) * 2024-01-30 2025-08-07 Sermonix Pharmaceuticals, Inc. Lasofoxifene treatment of er+ cancers with constitutively active esr1 mutations
CN119842900A (zh) * 2025-01-17 2025-04-18 厦门飞朔生物技术有限公司 一种可用于乳腺癌内分泌耐药治疗指导的人esr1基因突变检测试剂盒

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120052508A1 (en) 2010-08-27 2012-03-01 Rutgers, The State University Of New Jersey Genetic markers and diagnostic methods for resistance of breast cancer to hormonal therapies
US20150258099A1 (en) 2014-03-13 2015-09-17 Genentech, Inc. Methods and compositions for modulating estrogen receptor mutants

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6060503A (en) 1991-12-02 2000-05-09 Endorecherche, Inc. Benzopyran-containing compounds and method for their use
US5552412A (en) 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
UA51676C2 (uk) 1995-11-02 2002-12-16 Пфайзер Інк. (-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція
HN1996000101A (es) 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
IL120266A (en) 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
US20040044080A1 (en) 1997-10-28 2004-03-04 Place Virgil A. Treatment of dyspareunia with topically administered nitroglycerin formulations
US6277834B1 (en) 1998-06-19 2001-08-21 Senju Pharmaceutical Co. Ltd. Agents for relieving side effects of adrenal cortex hormone
YU26700A (sh) 1999-05-24 2002-06-19 Pfizer Products Inc. Postupak za cis-1-(2-(4-(6-metoksi-2-fenil-1,2,3,4- tetrahidronaftalen-1-il)fenoksi)etil)pirolidin
EP1086692A3 (en) 1999-07-28 2003-07-09 Pfizer Products Inc. Estrogen agonists and antagonists for multiple indications
US6436977B1 (en) 1999-09-29 2002-08-20 Pfizer Inc. Dosing regimens for lasofoxifene
CO5271697A1 (es) 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona
CN1400904A (zh) 2000-01-28 2003-03-05 恩多研究公司 与雌激素联合的选择性雌激素受体调节剂
DE10039199A1 (de) 2000-08-10 2002-02-21 Schering Ag Kombinationspräparate aus einem ERß selektiven Estrogen und einem SERM oder Antiestrogen
PT1318837E (pt) 2000-08-11 2004-12-31 Wyeth Corp Metodo de tratamenton de carcinoma positivo a receptor de estrogenio
AU2002235348A1 (en) 2001-01-17 2002-07-30 Praecis Pharmaceuticals Inc. Methods for treating hormone associated conditions using a combination of lhrh antagonists and specific estrogen receptor modulators
AU781168B2 (en) 2001-01-26 2005-05-12 Pfizer Products Inc. Method of treating certain cancers using an estrogen agonist/antagonist
PL372727A1 (en) 2002-03-28 2005-07-25 Pfizer Products Inc. Purified lasofoxifene and a method for purification of racemic lasofoxifene by recrystallization
PA8576201A1 (es) 2002-07-10 2004-05-26 Pfizer Prod Inc Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco
SG155258A1 (en) 2004-10-20 2009-09-30 Endorech Inc Sex steroid precursors alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 cgmp phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausa
US20090012052A1 (en) 2006-11-09 2009-01-08 Ore Pharmaceuticals Inc. Method for treating er+ breast cancer
US20110015134A1 (en) 2007-04-16 2011-01-20 Retsky Michael W Method of treatment for early stage cancer
CZ2007373A3 (cs) 2007-05-29 2008-12-10 Zentiva, A. S Zpusob prípravy lasofoxifenu
CA2725390C (en) 2008-04-08 2014-09-23 Syndax Pharmaceuticals, Inc. Use of a hdac inhibitor and a her-2 inhibitor in the treatment of breast cancer
US20100029734A1 (en) * 2008-05-06 2010-02-04 Ore Pharmaceuticals Inc. Methods for breast cancer screening and treatment
MX2011008073A (es) 2009-01-30 2011-11-18 Glaxosmithkline Llc Hidrocloruro de n-{(1-s)-2-amino -1-[(3-fluorofenil)metil]etil}-5- cloro-4-(4-cloro-1-metil-1h-pirazol-5-il)-2-tiofenocarboxamida cristalino.
EP2239570A1 (en) * 2009-04-10 2010-10-13 PamGene B.V. Method for determining the estrogen receptor status of breast cancer
ES2826950T3 (es) * 2009-05-27 2021-05-19 Ptc Therapeutics Inc Métodos para tratar cáncer y afecciones no neoplásicas
US20130253035A1 (en) 2010-08-16 2013-09-26 Duke University Camkk-beta as a target for treating cancer
CN103562226A (zh) 2011-03-11 2014-02-05 梅里麦克制药股份有限公司 使用egfr家族受体的抑制剂来治疗激素难治性乳腺癌
EP2709661A4 (en) 2011-05-18 2015-01-28 Merck Sharp & Dohme COMBINATIONS OF THERAPEUTIC ANTI-IGF1R
WO2013056178A2 (en) 2011-10-14 2013-04-18 Foundation Medicine, Inc. Novel estrogen receptor mutations and uses thereof
CN104169266A (zh) 2011-12-16 2014-11-26 奥乐玛药物股份有限公司 新的苯并吡喃化合物、其组合物和用途
US20160038506A1 (en) 2012-02-14 2016-02-11 Repros Therapeutics Inc. Selective Estrogen Receptor Modulators With Short Half-Lives and Uses Thereof
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US9204286B1 (en) 2013-03-15 2015-12-01 Sprint Communications Company L.P. System and method of branding and labeling a mobile device
CA2940576A1 (en) 2014-03-13 2015-09-17 F. Hoffmann-La Roche Ag Therapeutic combinations with estrogen receptor modulators
FI3834824T3 (fi) 2014-03-28 2025-12-05 Univ Duke Estrogeenireseptoripositiivisen rintasyövän hoito selektiivisellä estrogeenireseptorin modulaattorilla
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
CN113101292B (zh) 2014-05-08 2023-07-11 上海市生物医药技术研究院 双炔失碳酯组合物和疾病治疗方法
AU2015341700A1 (en) 2014-11-07 2017-06-08 Lipoxen Technologies Limited Method for treatment of primary hormone resistant endometrial and breast cancers
AU2016247674A1 (en) 2015-04-14 2017-10-19 Atossa Genetics Inc. Compositions and methods of treatment of breast disorders and estrogen-related disorders
MX393599B (es) * 2015-04-29 2025-03-19 Radius Pharmaceuticals Inc Rad1901 para usarse en el tratamiento de cancer en sujetos con cancer positivo a receptor de estrogeno alfa resistente a farmaco
WO2018071437A1 (en) 2016-10-11 2018-04-19 Sermonix Pharmaceuticals, Llc Lasofoxifene treatment of vva and osteoporosis in survivors of breast cancer and other malignancies
IL284875B (en) 2016-10-11 2022-07-01 Univ Duke Zofoxifene treatment for breast cancer
EP3568132B1 (en) 2017-01-10 2025-12-03 Wang, Wei Lasofoxifene modulation of membrane-initiated estrogen signals and methods for tumor treatment
EP3773524B1 (en) 2018-04-10 2025-04-09 Duke University Lasofoxifene for the treatment of er+ breast cancer carrying the mutation d538g or y537s
EP3837548A2 (en) * 2018-08-17 2021-06-23 F. Hoffmann-La Roche AG Diagnostic and therapeutic methods for the treatment of breast cancer
JP2024538689A (ja) 2021-10-05 2024-10-23 デューク ユニバーシティ 腫瘍免疫の小分子制御因子を含む組成物及びその使用方法
GB202116903D0 (en) 2021-11-18 2022-01-05 Sermonix Pharmaceuticals Inc Lasofoxifene treatment of aromatase-resistant er+ cancer
EP4531848A1 (en) 2022-05-25 2025-04-09 Sermonix Pharmaceuticals, Inc. Lasofoxifene combination treatment of er+ breast cancer that has progressed on a cdk4/6 inhibitor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120052508A1 (en) 2010-08-27 2012-03-01 Rutgers, The State University Of New Jersey Genetic markers and diagnostic methods for resistance of breast cancer to hormonal therapies
US20150258099A1 (en) 2014-03-13 2015-09-17 Genentech, Inc. Methods and compositions for modulating estrogen receptor mutants

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Andrea Z. LaCroix et al. Breast Cancer Incidence in the Randomized PEARL Trial of Lasofoxifene in Postmenopausal Osteoporotic Women, J Natl Cancer Lnst, pp.1706-1715 (2010.11.04.)

Also Published As

Publication number Publication date
RU2019114079A (ru) 2020-11-13
US10905659B2 (en) 2021-02-02
KR20240007720A (ko) 2024-01-16
TW201817422A (zh) 2018-05-16
RU2019114079A3 (enExample) 2021-07-23
TW202137980A (zh) 2021-10-16
PT3525774T (pt) 2022-03-30
TW202313005A (zh) 2023-04-01
US11980597B2 (en) 2024-05-14
WO2018093484A1 (en) 2018-05-24
TWI790672B (zh) 2023-01-21
WO2018071440A1 (en) 2018-04-19
KR20190092377A (ko) 2019-08-07
SG11201903236SA (en) 2019-05-30
KR20220151017A (ko) 2022-11-11
JP7247241B2 (ja) 2023-03-28
CA3040266A1 (en) 2018-05-24
US12414924B2 (en) 2025-09-16
KR102462433B1 (ko) 2022-11-03
ZA201902454B (en) 2022-09-28
JP7774896B2 (ja) 2025-11-25
TWI836808B (zh) 2024-03-21
TWI896001B (zh) 2025-09-01
PL3525774T3 (pl) 2022-04-25
JP2021073316A (ja) 2021-05-13
IL284875B (en) 2022-07-01
AU2022246480A1 (en) 2022-12-08
AU2022246480B2 (en) 2024-11-07
JP2019529581A (ja) 2019-10-17
US20250064757A1 (en) 2025-02-27
JP2023033415A (ja) 2023-03-10
AU2025200327A1 (en) 2025-02-06
CN110099680A (zh) 2019-08-06
EP3525774B1 (en) 2021-12-29
US20190231718A1 (en) 2019-08-01
US20180221335A1 (en) 2018-08-09
KR102623130B1 (ko) 2024-01-10
NZ752443A (en) 2022-11-25
AU2017360365A1 (en) 2019-05-02
JP6892151B2 (ja) 2021-06-23
US10258604B2 (en) 2019-04-16
IL265938A (en) 2019-05-30
JP7418052B2 (ja) 2024-01-19
US20210361596A1 (en) 2021-11-25
KR102285453B1 (ko) 2021-08-05
US20230233490A1 (en) 2023-07-27
US20240366534A1 (en) 2024-11-07
MX2019004184A (es) 2019-09-27
DK3525774T3 (da) 2022-03-14
EP3525774A1 (en) 2019-08-21
AU2017360365B2 (en) 2022-08-04
SG10201913951YA (en) 2020-03-30
TWI729227B (zh) 2021-06-01
MX387856B (es) 2025-03-19
CN112353796A (zh) 2021-02-12
EP4035662A1 (en) 2022-08-03
NZ793063A (en) 2025-09-26
US20190151286A1 (en) 2019-05-23
JP2024026527A (ja) 2024-02-28
BR112019007254A2 (pt) 2019-07-02
IL265938B (en) 2021-08-31
KR20210096316A (ko) 2021-08-04
KR20230042390A (ko) 2023-03-28
MX2021013911A (es) 2022-01-18
US20180098963A1 (en) 2018-04-12
IL284875A (en) 2021-08-31
ES2909576T3 (es) 2022-05-09
CN110099680B (zh) 2021-02-05
CN112933082A (zh) 2021-06-11
TW202446367A (zh) 2024-12-01

Similar Documents

Publication Publication Date Title
KR102531354B1 (ko) Er+ 유방암의 라소폭시펜 치료
HK40077706A (en) Lasofoxifene treatment of er+ breast cancer
HK40005311A (en) Lasofoxifene treatment of er+ breast cancer
HK40005311B (en) Lasofoxifene treatment of er+ breast cancer

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20230310

Application number text: 1020227037620

Filing date: 20221027

PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20230310

Comment text: Request for Examination of Application

PG1501 Laying open of application
E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20230329

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20230508

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20230509

End annual number: 3

Start annual number: 1

PG1601 Publication of registration